Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Nuvectis Pharma Inc NVCT
$20.22
โผ -6.52%
($-1.41)
⬇️ Below Yest. Low
Open
$21.81
Prev Close
$21.63
Day Range
$20.22 โ $21.95
52W Range
$5.55 โ $29.28
Market Cap
$660.06M
Beta
-0.24
EPS (TTM)
$-1.20
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-02-04 |
| Shares Out. | 31,530,000 |
| Website | nuvectis.com/ โ |
| Phone | 13608377232 |
| Employees | 13 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$7.0M |
| Free Cash Flow | -$19.5M |
| Total Assets | $22.4M |
| Total Liabilities | $13.3M |
| Equity | $9.1M |
About Nuvectis Pharma Inc
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Nuvectis Pharma Inc is a publicly traded company under the ticker symbol NVCT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
11 analysts (2026-09-01)

